{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:10:47Z","timestamp":1789902647208,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"SMHC Clinical Research Center","award":["CRC2017ZD03"],"award-info":[{"award-number":["CRC2017ZD03"]}]},{"name":"Shanghai Clinical Research Center for Mental Health"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.schres.2020.11.010","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T08:41:58Z","timestamp":1606898518000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design"],"prefix":"10.1016","volume":"230","author":[{"given":"Xuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2738-3868","authenticated-orcid":false,"given":"Xiaoyun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-8924","authenticated-orcid":false,"given":"Xiaoduo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoufu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matcheri S.","family":"Keshavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaida","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengtang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2020.11.010_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/jcp.0b013e3180d0a6d4","article-title":"Early use of clozapine for poorly responding first-episode psychosis","volume":"27","author":"Agid","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.schres.2020.11.010_bb0400","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis[J]","volume":"72","author":"Agid","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ajp.2012.12060778","article-title":"Clozapine\u2019s role in the treatment of first-episode schizophrenia","volume":"170","author":"Remington","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2013.04.027","article-title":"Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5","volume":"150","author":"Barch","year":"2013","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2020.11.010_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2013revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophr. Res."},{"issue":"10100","key":"10.1016\/j.schres.2020.11.010_bb0040","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0045","first-page":"CD001359","article-title":"Olanzapine for schizophrenia","volume":"2","author":"Duggan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6940","key":"10.1016\/j.schres.2020.11.010_bb0050","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bmj.308.6940.1311","article-title":"Risperidone for schizophrenia","volume":"308","author":"Edwards","year":"1994","journal-title":"BMJ Clinical Research"},{"key":"10.1016\/j.schres.2020.11.010_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1155\/2011\/394896","article-title":"Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: a pilot study","volume":"2011","author":"Edwards","year":"2011","journal-title":"Schizophr Res Treatment"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0060","first-page":"CD004578","article-title":"Aripiprazole for schizophrenia","volume":"2","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database Systematic Reviews"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2020.11.010_bb0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1192\/bjp.bp.112.112300","article-title":"Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study)","volume":"202","author":"Hastrup","year":"2013","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"issue":"10202","key":"10.1016\/j.schres.2020.11.010_bb0085","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.12m08001","article-title":"Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization","volume":"74","author":"Jin","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2020.11.010_bb0095","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.4088\/JCP.13m08606","article-title":"The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis","volume":"75","author":"Jordan","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"9618","key":"10.1016\/j.schres.2020.11.010_bb0100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.schres.2020.11.010_bb0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1185\/03007999909113374","article-title":"Patient satisfaction with, and acceptability of, atypical antipsychotics","volume":"15","author":"Kalali","year":"1999","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0115","first-page":"345","article-title":"Pharmacologic treatment of schizophrenia","volume":"12","author":"Kane","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS consensus cognitive battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatr."},{"issue":"10","key":"10.1016\/j.schres.2020.11.010_bb0130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0006-3223(01)01223-9","article-title":"Strengthening clinical effectiveness trials: equipoise-stratified randomization","volume":"50","author":"Lavori","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2020.11.010_bb0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"issue":"9896","key":"10.1016\/j.schres.2020.11.010_bb0150","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0155","first-page":"378","article-title":"The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"14","author":"Leucht","year":"2016","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"11","key":"10.1016\/j.schres.2020.11.010_bb0165","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2020.11.010_bb0170","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2020.11.010_bb0175","first-page":"781","article-title":"Abnormal Involuntary Movement Scale (AIMS)","volume":"24","author":"Listed","year":"1988","journal-title":"Psychopharmacol. Bull."},{"issue":"6","key":"10.1016\/j.schres.2020.11.010_bb0180","first-page":"376","article-title":"Use of personalized Dynamic Treatment Regimes (DTRs) and Sequential Multiple Assignment Randomized Trials (SMARTs) in mental health studies","volume":"26","author":"Liu","year":"2014","journal-title":"Shanghai Arch. Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2020.11.010_bb0185","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2011.07.022","article-title":"Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia","volume":"132","author":"Mausbach","year":"2011","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2020.11.010_bb0195","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"Journal of Sex & Marital Therapy"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.11.010_bb0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/CEOR.S44325","article-title":"The personal, societal, and economic burden of schizophrenia in the People\u2019s Republic of China: implications for antipsychotic therapy","volume":"5","author":"Montgomery","year":"2013","journal-title":"Clinicoecon Outcomes Res: CEOR"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0215","first-page":"CD001357","article-title":"Amisulpride for schizophrenia","volume":"2002","author":"Mota","year":"2002","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.schres.2020.11.010_bb0220","series-title":"Prediction of Neuroleptic Treatment Outcome in Schizophrenia","article-title":"Subjective effects of neuroleptics predict compliance","author":"Naber","year":"1994"},{"issue":"1\u20132","key":"10.1016\/j.schres.2020.11.010_bb0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14737167.2018.1430571","article-title":"A systematic review of health economic models and utility estimation methods in schizophrenia","volume":"18","author":"Nemeth","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","author":"Osser","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.schres.2020.11.010_bb0245","series-title":"Encyclopedia of Psychopharmacology","first-page":"303","article-title":"Clinical global impression scales","author":"Padhi","year":"2010"},{"issue":"4","key":"10.1016\/j.schres.2020.11.010_bb0250","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jval.2014.02.008","article-title":"Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia","volume":"17","author":"Park","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1176\/appi.ajp.2014.13060787","article-title":"Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study","volume":"172","author":"Petrides","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0260","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.schres.2013.07.014","article-title":"Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0265","first-page":"92","article-title":"The DSM-5: classification and criteria changes","volume":"12","author":"Regier","year":"2013","journal-title":"World Psychiatry Official Journal of the World Psychiatric Association"},{"issue":"9","key":"10.1016\/j.schres.2020.11.010_bb0270","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2020.11.010_bb0280","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2020.11.010_bb0285","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/schbul\/sbv224","article-title":"Cost-effectiveness of comprehensive, integrated care for first episode psychosis in the NIMH RAISE early treatment program","volume":"42","author":"Rosenheck","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2020.11.010_bb0290","first-page":"424","article-title":"A systematic translation and cultural adaptation process for Three-Factor Eating Questionnaire (TFEQ-R21)","volume":"68","author":"Rosnah","year":"2013","journal-title":"Med. J. Malays."},{"issue":"11","key":"10.1016\/j.schres.2020.11.010_bb0295","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.schres.2020.11.010_bb0300","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.schres.2020.11.010_bb0305","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/11314280-000000000-00000","article-title":"Antipsychotic drugs for first-episode schizophrenia: a comparative review","volume":"23","author":"Salimi","year":"2009","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.schres.2020.11.010_bb0310","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.11.010_bb0315","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.psychres.2012.07.005","article-title":"One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis","volume":"200","author":"San","year":"2012","journal-title":"Psychiatry Res."},{"issue":"9162","key":"10.1016\/j.schres.2020.11.010_bb0320","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(98)07549-7","article-title":"Schizophrenia","volume":"353","author":"Schultz","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2020.11.010_bb0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2018.06.070","article-title":"The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review","volume":"268","author":"Shah","year":"2018","journal-title":"Psychiatry Res."},{"issue":"Suppl. 20","key":"10.1016\/j.schres.2020.11.010_bb0335","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.11.010_bb0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2015.09.003","article-title":"The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China","volume":"169","author":"Shi","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.11.010_bb0345","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.schres.2019.01.034","article-title":"What is the optimal neuropsychological test battery for schizophrenia in China?","volume":"208","author":"Shi","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.11.010_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.schres.2020.11.010_bb0355","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674371005500303","article-title":"The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review","volume":"55","author":"Sinyor","year":"2010","journal-title":"Can. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.11.010_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2020.11.010_bb0365","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, Quetiapine and Risperidone?--a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2020.11.010_bb0370","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ps.201600041","article-title":"Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program","volume":"68","author":"Tang","year":"2017","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.schres.2020.11.010_bb0375","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.schres.2020.11.010_bb0380","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"Ucok","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2020.11.010_bb0385","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2020.11.010_bb0390","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2020.11.010_bb0395","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420305296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420305296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:51Z","timestamp":1760298111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420305296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":75,"alternative-id":["S0920996420305296"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.11.010","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}